Gareth Morgan, MD, PhD, is Director of Multiple Myeloma Research at NYU Langone Perlmutter Cancer Center in New York, NY. He is an internationally recognized clinician-scientist in the molecular genetics of blood cell cancers and myeloma treatment. He has a particular focus on diagnostic prevention and treatment strategies for high-risk and relapsed/refractory myeloma. Dr. Morgan is doing influential work on the characterization of the myeloma genome, defining specific subsets of the disease that have prognostic importance, and developing personalized therapeutic strategies targeted to each subtype. He is also engaged in advanced research in molecular diagnostics, drug development, and clinical trials. His research aims to cure myeloma and to reduce side effects by targeting treatment to the biology underlying each patient’s cancer. Prior to leading the Perlmutter Cancer Center’s myeloma program, Dr. Morgan was Professor of Medicine and Director of the Myeloma Institute at the University of Arkansas for Medical Sciences and Professor of Hematology and Director of the Centre for Myeloma Research at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London, Europe’s largest comprehensive cancer institute. He is also a founding director of the European Myeloma Network and has authored more than 500 peer-reviewed journals. Dr. Morgan received his doctorate on the genetics of leukemia from the University of London in 1991 and his bachelor of medicine in 1981 from the Welsh National School of Medicine. His post graduate medical training was completed in Wales and at the Royal Postgraduate Medical School in London.

Jens Hillengass, MD, PhD, is Professor of Oncology and Chief of the Myeloma and Amyloidosis Service at Roswell Park Cancer Institute in Buffalo, NY. Prior to joining Roswell, he was the deputy of the section multiple myeloma of the University Hospital of Heidelberg, Germany, the leader of its autologous stem cell transplantation program, and head of the hemato-oncological imaging research group at the German Cancer Research Center (DKFZ). He completed his medical degree at Heidelberg University, where he later completed residency and fellowship in the department of hematology, oncology, and rheumatology. Dr Hillengass received a Gerok scholarship to study radiology at the German Cancer Research Center. Additionally, he completed a research fellowship at the National Cancer Institute. Dr. Hillengass is member of the Black Swan Research Initiative of the International Myeloma Foundation and the International Myeloma Working Group where he co-chairs the bone and imaging group.

Dr. Ravi Vij is Jeffrey S and Prue H Distinguished Professor of Medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, where he specializes in hematologic malignancies with an academic focus on Multiple Myeloma, transplant, and cellular therapies. He also serves as Director of the Multiple Myeloma Program and as Medical Director for Satellite Operations in the Division of Oncology. Dr. Vij pursued his medical education at Maulana Azad Medical College in New Delhi, India, before completing postgraduate training in the United Kingdom. He subsequently moved to the United States, where he undertook an internal medicine residency at Rush University in Chicago, followed by fellowships in medical oncology/hematology and bone marrow transplantation at Washington University. Since joining the faculty in 2000, he has advanced through the academic ranks to full Professor of Medicine. His career has been dedicated to advancing treatment for multiple myeloma and related blood cancers. He currently serves as Senior Editor for the journal Clinical Lymphoma, Myeloma and Leukemia and has served on the Cancer and Leukemia Group B (CALGB/Alliance) Myeloma, Leukemia, and Transplant Committees, the Multiple Myeloma Research Consortium Steering Committee, Clinical Trials Network Myeloma Committee, American Society of Clinical Oncology education and scientific committees, and as Chair of the ASH Scientific Committee on Plasma Cell Dyscrasias. Dr. Vij leads a programmatic effort to further research in multiple myeloma. As the Principal Investigator for the Multiple Myeloma Tissue Banking initiative, he has fostered several collaborative efforts with laboratory researchers at Washington University to study the mutational landscape and clonal heterogeneity of multiple myeloma and its microenvironment. An active clinical investigator, Dr. Vij has led and contributed to numerous pivotal clinical trials that have shaped the modern therapeutic landscape of multiple myeloma. His research includes early development of proteasome inhibitors and immunomodulatory drugs, monoclonal antibodies, novel transplant approaches, immunotherapies including CAR-T cells, bispecific antibodies, and genomics-driven strategies. He has authored more than 300 peer-reviewed manuscripts in leading journals, including The New England Journal of Medicine, Blood, Journal of Clinical Oncology and Leukemia. Dr. Vij has mentored more than 25 fellows in clinical research, nurturing the development of future leaders in hematology and oncology. His contributions have been recognized with multiple honors, including the Multiple Myeloma Research Foundation Innovator Award, the Center of Excellence Award, and the Leukemia & Lymphoma Society Visionary of the Year Award (2023). He has also been repeatedly listed in Best Doctors in America and received the Teacher of the Year Award from the Hematology/Oncology Fellowship Program, underscoring his enduring commitment to education and mentorship.